Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer

13 Apr 2017

Abstract excerpt

PURPOSE: More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments. METHODS: We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Ferroptosis and cancer prognosis
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28409241
DOI: 10.1007/s10549-017-4234-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancerPMID 28409241Read ↗

Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity Read ↗

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular SubtypesSemantic proximity Read ↗

Prognostic Predictors Do Not Equate to Predictors of Chemotherapy Benefit in HR-Positive, HER2-Negative Breast Cancer: A Population-Based StudySemantic proximity Read ↗

Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBCSemantic proximity Read ↗

Bioinformatics-based analysis of TCGA to identify the prognostic biomarkers in HR-positive/HER2-negative tamoxifen-treated breast cancerSemantic proximity Read ↗

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read ↗

Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk.Semantic proximity Read ↗

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read ↗

MMP1 acts as an independent prognostic biomarker correlated with immune infiltration in breast cancerSemantic proximity Read ↗

The relationship between hormone receptor status, tumor size and clinical stage and the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer, predictors of survival, and the establishment of Cox-Based risk prediction model and nomogramSemantic proximity Read ↗

Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.Semantic proximity Read ↗

Identification of markers to predict benefit from trastuzumab treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.